Company VitaSpring Biomedical Co. Ltd. Other OTC
Equities
VSBC
US92851B1026
Biotechnology & Medical Research
Business Summary
Sales per Business
USD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Cellular Drugs
100.0
%
| 0 | 100.0 % | 6 | 100.0 % | +2,161.56% |
Sales per region
USD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | 100.0 % | 6 | 100.0 % | +2,161.56% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Cheng Hsiang Kao
CEO | Chief Executive Officer | - | 20/01/20 |
Pao Chi Chu
CHM | Chairman | 70 | 20/01/20 |
Jer Li Lin
CTO | Chief Tech/Sci/R&D Officer | - | 20/01/20 |
Yen Xun Chen
PRN | Corporate Officer/Principal | - | 20/01/20 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Pao Chi Chu
CHM | Chairman | 70 | 20/01/20 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 206,520,030 | 85,148,035 ( 41.23 %) | 0 | 41.23 % |
Company contact information
VitaSpring Biomedical Co. Ltd.
400 Spectrum Center Drive Suite 1620
92618, Irvine
+
Sector
1st Jan change | Capi. | |
---|---|---|
+7.52% | 113B | |
+11.38% | 106B | |
-12.64% | 22.22B | |
+0.44% | 22.27B | |
-4.18% | 19.43B | |
-37.85% | 17.87B | |
-8.58% | 17.24B | |
+37.41% | 12.52B | |
-23.95% | 8.34B |